Companies › ARCE Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ARD103 anti-CLL-1 CAR-T cell therapy | CLEC12A | Phase 1 | Acute Myeloid Leukemia, in Relapse | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06680752 | ARD103 | Phase 1 | Acute Myeloid Leukemia, in Relapse | Hematology | Oct 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.